BCMA嵌合抗原受体T细胞疗法中的血细胞减少：揭示炎症机制 - Suppr

Suppr

超能文献

Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms.

作者信息

Sperling Adam S

机构信息

Division of Hematology, Brigham and Women's Hospital, Boston, MA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

Blood Adv. 2024 Nov 12;8(21):5527-5528. doi: 10.1182/bloodadvances.2024014308.

DOI:10.1182/bloodadvances.2024014308

PMID:39446348

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11544301/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5e9/11544301/1e08ad11c921/BLOODA_ADV-2024-014308-C-gr1.jpg

相似文献

Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms.BCMA嵌合抗原受体T细胞疗法中的血细胞减少：揭示炎症机制

Blood Adv. 2024 Nov 12;8(21):5527-5528. doi: 10.1182/bloodadvances.2024014308.

Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows.抗BCMA嵌合抗原受体T细胞疗法后持续血细胞减少与治疗后骨髓造血活性降低有关。

Am J Clin Pathol. 2024 Jul 20. doi: 10.1093/ajcp/aqae083.

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.在复发/难治性多发性骨髓瘤中，靶向BCMA的嵌合抗原受体T细胞（CAR T细胞）疗法后T细胞亚群的变化、既往血细胞减少症和高铁蛋白血症与血细胞减少症相关：一项前瞻性综合生物标志物研究的结果

Br J Haematol. 2024 Sep;205(3):999-1010. doi: 10.1111/bjh.19515. Epub 2024 May 8.

Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤老年患者中的安全性和疗效。

Transplant Cell Ther. 2023 Jun;29(6):350-355. doi: 10.1016/j.jtct.2023.03.012. Epub 2023 Mar 17.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.CAR-HEMATOTOX 评分作为接受 BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤患者毒性和反应的预后模型。

J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.

Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.BCMA 靶向 CAR T 细胞治疗后造血恢复延迟时使用 CD34+ 干细胞增强的疗效和安全性。

Transplant Cell Ther. 2023 Sep;29(9):567-571. doi: 10.1016/j.jtct.2023.05.012. Epub 2023 May 22.

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.通过单细胞测序鉴定复发/难治性多发性骨髓瘤中BCMA嵌合抗原受体T细胞（CAR-T）疗法复发的潜在耐药机制和治疗靶点。

Exp Hematol Oncol. 2023 May 8;12(1):44. doi: 10.1186/s40164-023-00402-5.

[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].[两例在鼠源BCMA CAR-T细胞治疗后进展的难治性多发性骨髓瘤患者的人源化BCMA CAR-T细胞挽救治疗]

Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):502-507. doi: 10.3760/cma.j.issn.0253-2727.2021.06.010.

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.APRIL 和基于抗体片段的骨髓瘤 CAR T 细胞均可通过 trogocytosis 和内化诱导 BCMA 下调。

J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005091.

本文引用的文献

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.促进多发性骨髓瘤患者在接受 BCMA CAR-T 治疗后长期细胞减少症的分子机制。

Blood Adv. 2024 Nov 12;8(21):5479-5492. doi: 10.1182/bloodadvances.2023012522.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.CD19 CAR T 细胞治疗后细胞减少症持续时间长与克隆性扩增 IFNγ 表达 CD8 T 细胞骨髓浸润有关。

Cell Rep Med. 2023 Aug 15;4(8):101158. doi: 10.1016/j.xcrm.2023.101158.

J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。

N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.免疫效应细胞相关性噬血细胞性淋巴组织细胞增生症样综合征。

Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。

N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.

Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.克隆性造血与 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤时严重神经毒性风险增加相关。

Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177.

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗患者的克隆性造血。

Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554.

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。

Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.

Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection.炎症作为疾病、衰老和克隆选择中造血干细胞功能的调节剂。

J Exp Med. 2021 Jul 5;218(7). doi: 10.1084/jem.20201541. Epub 2021 Jun 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验